Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Background & Aims Cancer stem cells (CSCs) can contribute to hepatocellular carcinoma (HCC) progression and recurrence following therapy. The presence of tumor-associated macrophages (TAMs) in patients with HCC is associated with poor outcomes. It is not clear whether TAMs interact with CSCs during HCC development. We investigated whether TAMs affect the activities of CSCs in the microenvironment of human HCCs. Methods HCCs were collected from 17 patients during surgical resection and single cell suspensions were analyzed by flow cytometry. CD14+ TAMs were isolated from the HCC cell suspensions and placed into co-culture with HepG2 or Hep3B cells, and CSC functions were measured. The interleukin 6 (IL6) receptor was blocked with a monoclonal antibody (tocilizumab), and STAT3 was knocked down with small hairpin RNAs in HepG2 cells. Xenograft tumors were grown in NOD-SCID/Il2Rgnull mice from human primary HCC cells or HepG2 cells. Results CD44+ cells from human HCCs and cell lines formed more spheres in culture and more xenograft tumors in mice than CD44− cells, indicating that CD44+ cells are CSCs. Incubation of the CD44+ cells with TAMs promoted expansion of CD44+ cells, and increased their sphere formation in culture and formation xenograft tumors in mice. In human HCC samples, numbers of TAMs correlated with numbers of CD44+ cells. Of all cytokines expressed by TAMs, IL6 was increased at the highest level in human HCC co-cultures, compared with TAMs not undergoing co-culture. IL6 was detected in the microenvironment of HCC samples and induced expansion of CD44+ cells in culture. Levels of IL6 correlated with stages of human HCCs and detection of CSC markers. Incubation of HCC cell lines with tocilizumab or knockdown of STAT3 in HCC cells reduced the ability of TAMs to promote sphere formation by CD44+ cells in culture and growth of xenograft tumors in mice. Conclusions CD44+ cells isolated from human HCC tissues and cell lines have CSC activities in vitro and form a larger number of xenograft tumors in mice than CD44− cells. TAMs produce IL6, which promotes expansion of these CSCs and tumorigenesis. Levels of IL6 in human HCC samples correlate with tumor stage and markers of CSCs. Blockade of IL6 signaling with tocilizumab, a drug approved by the Food and Drug Administration for treatment of rheumatoid arthritis, inhibits TAM-stimulated activity of CD44+ cells. This drug might be used to treat patients with HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Phenotypic characterization of human colorectal cancer stem cells
Dalerba, P., Dylla, S. J., Park, I.-K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703478104 · Cited by 2,184
Self-citationZhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Self-citation
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Self-citationMacrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,229
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Self-citationIL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
“Tumor-associated M2 macrophages not only promote tumor progression and metastasis by producing tumor growth factor and angiogenic factors, such as epidermal growth factor (EGF), VEGF and IL-6, but also inhibit tumor immunity by arginase-1, IL-10 and TGF β (211–214).”
BackgroundTargeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
IL-6 pathway in the liver: From physiopathology to therapy
Schmidt-Arras, D., & Rose-John, S. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.004 · Cited by 978
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Self-citationMuch More than M1 and M2 Macrophages, There are also CD169+ and TCR+ Macrophages
Chávez-Galán, L., Olleros, M. L., Vesin, D., & Garcia, I. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00263 · Cited by 653
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy
Komohara, Y., Fujiwara, Y., Ohnishi, K., & Takeya, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.009 · Cited by 612
Cancer stem cell–immune cell crosstalk in tumour progression
Bayik, D., & Lathia, J. D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00366-w · Cited by 561
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
Ju, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 516
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
Lee, T. K.-W., Guan, X.-Y., & Ma, S. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00508-3 · Cited by 460
Tumor‐associated macrophages in liver cancer: From mechanisms to therapy
Cheng, K., Cai, N., Zhu, J., Yang, X., Liang, H., & Zhang, W. (2022) · Cancer Communications · doi:10.1002/cac2.12345 · Cited by 460
Liu, J., Fan, L., Yu, H., Zhang, J., He, Y., Feng, D., Wang, F., Li, X., Liu, Q., Li, Y., et al. (2019) · Hepatology · doi:10.1002/hep.30607 · Cited by 449
Lu, C., Rong, D., Zhang, B., Zheng, W., Wang, X., Chen, Z., & Tang, W. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1047-6 · Cited by 418
Fu, Y., Liu, S., Zeng, S., & Shen, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1396-4 · Cited by 390
Tumor microenvironment and cancer therapy resistance
Sun, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.07.044 · Cited by 381
Tumor-Associated Macrophages: Implications in Cancer Immunotherapy
Petty, A. J., & Yang, Y. (2017) · Immunotherapy · doi:10.2217/imt-2016-0135 · Cited by 363
Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets
Klingenberg, M., Matsuda, A., Diederichs, S., & Patel, T. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.009 · Cited by 354
Shi, Y., Ping, Y.-F., Zhou, W., He, Z.-C., Chen, C., Bian, B.-S.-J., Zhang, L., Chen, L., Lan, X., Zhang, X.-C., et al. (2017) · Nature Communications · doi:10.1038/ncomms15080 · Cited by 344
Major pathways involved in macrophage polarization in cancer
Kerneur, C., Cano, C. E., & Olive, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026954 · Cited by 337
Emerging roles of ECM remodeling processes in cancer
Mohan, V., Das, A., & Sagi, I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.004 · Cited by 334
Tumor-associated macrophages: an effective player of the tumor microenvironment
Basak, U., Sarkar, T., Mukherjee, S., Chakraborty, S., Dutta, A., Dutta, S., Nayak, D., Kaushik, S., Das, T., & Sa, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295257 · Cited by 333
Cancer cell plasticity during tumor progression, metastasis and response to therapy
Pérez-González, A., Bévant, K., & Blanpain, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00595-y · Cited by 332
Monocytes in the Tumor Microenvironment
Ugel, S., Canè, S., De Sanctis, F., & Bronte, V. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013058 · Cited by 314
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Ruf, B., Heinrich, B., & Greten, T. F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 312
Liver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
Harmer, D., Falank, C., & Reagan, M. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00788 · Cited by 307
Functional and genetic deconstruction of the cellular origin in liver cancer
Marquardt, J. U., Andersen, J. B., & Thorgeirsson, S. S. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4017 · Cited by 306
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Role of nonresolving inflammation in hepatocellular carcinoma development and progression
Yu, L.-X., Ling, Y., & Wang, H.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0048-z · Cited by 301
Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis
Wang, X., Sun, W., Shen, W., Xia, M., Chen, C., Xiang, D., Ning, B., Cui, X., Li, H., Li, X., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.019 · Cited by 290
Peng, D., Tanikawa, T., Li, W., Zhao, L., Vatan, L., Szeliga, W., Wan, S., Wei, S., Wang, Y., Liu, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2528 · Cited by 274
Self-citationThe evolving concept of liver cancer stem cells
Nio, K., Yamashita, T., & Kaneko, S. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0572-9 · Cited by 274
Huang, R., Wang, S., Wang, N., Zheng, Y., Zhou, J., Yang, B., Wang, X., Zhang, J., Guo, L., Wang, S., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2435-y · Cited by 263
Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies
Liu, Y.-C., Yeh, C.-T., & Lin, K.-H. (2020) · Cells · doi:10.3390/cells9061331 · Cited by 253
Tumor-related interleukins: old validated targets for new anti-cancer drug development
Setrerrahmane, S., & Xu, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0721-9 · Cited by 237
“IL-6 mRNA was detected in 73% of HCC patients and significantly correlated with the expression of CD44 (an important CSCs marker), POU5F1, HIF-1α, β-catenin, Snail, and HEY1 [126].”
Wnt signaling pathway in cancer immunotherapy
Zhou, Y., Xu, J., Luo, H., Meng, X., Chen, M., & Zhu, D. (2022) · Cancer Letters · doi:10.1016/j.canlet.2021.10.034 · Cited by 233
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma
Xu, J., Lin, H., Wu, G., Zhu, M., & Li, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.760971 · Cited by 228
Tang, B., Zhu, J., Wang, Y., Chen, W., Fang, S., Mao, W., Xu, Z., Yang, Y., Weng, Q., Zhao, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202203973 · Cited by 221
miR‐28‐5p‐IL‐34‐macrophage feedback loop modulates hepatocellular carcinoma metastasis
Zhou, S., Hu, Z., Zhou, Z., Dai, Z., Wang, Z., Cao, Y., Fan, J., Huang, X., & Zhou, J. (2016) · Hepatology · doi:10.1002/hep.28445 · Cited by 209
“TAMs are known to participate in tumor progression,(20) and the mechanism underlying these roles has also been documented in several types of cancer, including HCC.(21,22) Interestingly, we found that after coculture with TAMs, HepG2 and Huh7 cells exhibited decreased miR-28-5p levels, accompanied by increased IL-34 e…”
BackgroundInfluentialHypoxia-inducible factors: a central link between inflammation and cancer
Triner, D., & Shah, Y. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84430 · Cited by 199
“TAMs directly promote tumor growth via direct secretion of cytokines such as IL-6, which induces tumor-cell STAT3 signaling to promote growth and stem cell expansion (74); these cells have been directly linked to tumor invasion and metastasis (75, 76).”
BackgroundBreast Cancer-Derived Exosomes Alter Macrophage Polarization via gp130/STAT3 Signaling
Ham, S., Lima, L. G., Chai, E. P. Z., Muller, A., Lobb, R. J., Krumeich, S., Wen, S. W., Wiegmans, A. P., & Möller, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00871 · Cited by 189
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
Bule, P., Aguiar, S. I., Aires-Da-Silva, F., & Dias, J. N. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189804 · Cited by 185
The emerging role of lncRNAs in the regulation of cancer stem cells
Castro-Oropeza, R., Melendez-Zajgla, J., Maldonado, V., & Vazquez-Santillan, K. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0406-4 · Cited by 178
He, Q., Liu, M., Huang, W., Chen, X., Zhang, B., Zhang, T., Wang, Y., Liu, D., Xie, M., Ji, X., et al. (2021) · Hepatology · doi:10.1002/hep.32062 · Cited by 177
“Intratumoral TAM and MDSC infiltration indicates poor prognosis in human HCC.(26,43) TAMs and MDSCs facilitate tumor progression and metastasis by inducing immunosuppression, promoting angiogenesis, and increasing tumor cell invasion.”
BackgroundInfluentialCancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications
Lau, E. Y.-T., Ho, N. P.-Y., & Lee, T. K.-W. (2017) · Stem Cells International · doi:10.1155/2017/3714190 · Cited by 167
“TGF-β1 and IL-6 are predominantly produced by TAMs in hepatocellular carcinoma (HCC), which induce EMT and activate the STAT3 pathway, respectively, to promote liver CSC properties [50, 51].”
BackgroundLai, S.-C., Su, Y.-T., Chi, C.-C., Kuo, Y.-C., Lee, K.-F., Wu, Y.-C., Lan, P.-C., Yang, M.-H., Chang, T.-S., & Huang, Y.-H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1442-2 · Cited by 128
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L. (2017) · Nature Communications · doi:10.1038/ncomms15433 · Cited by 123
Campana, L., Starkey Lewis, P. J., Pellicoro, A., Aucott, R. L., Man, J., O’Duibhir, E., Mok, S. E., Ferreira-Gonzalez, S., Livingstone, E., Greenhalgh, S. N., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701247 · Cited by 107
“Tumor-associated macrophages in HCC have a phenotype similar to restorative macrophages (63).”
BackgroundLi, M., Wang, L., Cong, L., Wong, C. C., Zhang, X., Chen, H., Zeng, T., Li, B., Jia, X., Huo, J., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000591 · Cited by 107
“…HCC, spatial We discovered a major increase in immune cell infiltration in HCC samples compared to healthy livers, particularly immunosuppressive MDSCs and TAMs, in keeping with the fact that these cells were frequently enriched in cancers [27,28] and their protumorigenic potential.”
BackgroundTruong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Prognostic value of the systemic inflammation response index in human malignancy: A meta-analysis
Wei, L., Xie, H., & Yan, P. (2020) · Medicine · doi:10.1097/md.0000000000023486 · Cited by 93
Huang, L., Hu, B., Ni, J., Wu, J., Jiang, W., Chen, C., Yang, L., Zeng, Y., Wan, R., Hu, G., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0301-7 · Cited by 86
RetractedRosenberg, N., Van Haele, M., Lanton, T., Brashi, N., Bromberg, Z., Adler, H., Giladi, H., Peled, A., Goldenberg, D. S., Axelrod, J. H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.029 · Cited by 72
Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma
Koo, S.-Y., Park, E.-J., & Lee, C.-W. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0480-3 · Cited by 47
Physical activity and risk of hepatocellular carcinoma: a systematic review and meta-analysis
DiJoseph, K., Thorp, A., Harrington, A., Schmitz, K. H., Chinchilli, V. M., & Stine, J. G. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07601-w · Cited by 25
Arechederra, M., & Fernández-Barrena, M. G. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.008 · Cited by 9
Metadata
- Authors
- Wan, S., Zhao, E., Kryczek, I., Vatan, L., Sadovskaya, A., Ludema, G., Simeone, D. M., Zou, W., & Welling, T. H.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 147
- Issue
- 6
- Pages
- 1393-1404
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2000799034
- Cited by
- 675
- References
- 41
- FWCI
- 16.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.